
{
  "Company Overview": {
    "Name": "Bajaj Healthcare Ltd",
    "Sector": "Pharmaceuticals",
    "Industry": "Pharmaceuticals - Indian - Bulk Drugs & Formln",
    "Business Description": "Incorporated in 1993, Bajaj Healthcare Ltd manufactures a wide range of Active Pharmaceutical Ingredients and Formulations. BHL is focused on development, supply, manufacturing of Amino Acids, Nutritional Supplements and Active Pharma Ingredients for Pharmaceutical, Nutraceuticals and Food industries. It manufactures active pharmaceutical ingredients and formulations in the form of tablets, capsules, powder, etc. for ~ 550+ clients, exporting bulk drugs to ~ 62+ countries in Europe, USA, Africa, Australia, etc.",
    "Market Position": "Information not explicitly provided, but peer comparison data suggests a smaller market cap compared to competitors."
  },
  "Financial Metrics": {
    "Market Cap": "₹ 1,686 Cr.",
    "Current Price": "₹ 534",
    "High / Low": "₹ 615 / ₹ 263",
    "Stock P/E": "49.3",
    "Book Value": "₹ 141",
    "Dividend Yield": "0.19 %",
    "ROCE": "8.23 %",
    "ROE": "-12.2 %",
    "Face Value": "₹ 5.00",
    "Debt-to-Equity Ratio": "Information not explicitly provided." 
  },
  "Performance Trends": {
    "Quarterly Results": {
      "Sales": [167.57, 175.71, 163.79, 195.32, 132.57, 154.11, 129.74, 101.21, 108.57, 133.90, 132.25, 133.09],
      "Expenses": [136.75, 150.50, 139.33, 160.89, 102.13, 132.08, 108.00, 82.27, 89.04, 117.87, 107.75, 108.56],
      "Operating Profit": [30.82, 25.21, 24.46, 34.43, 30.44, 22.03, 21.74, 18.94, 19.53, 16.03, 24.50, 24.53],
      "OPM %": ["18.39%", "14.35%", "14.93%", "17.63%", "22.96%", "14.29%", "16.76%", "18.71%", "17.99%", "11.97%", "18.53%", "18.43%"],
      "Net Profit": [17.45, 17.47, 12.02, 16.36, 11.05, 3.59, -48.21, -3.46, -2.20, -29.92, 7.13, 9.46],
      "EPS in Rs": [6.32, 6.33, 4.36, 5.93, 4.00, 1.30, -17.47, -1.25, -0.80, -10.84, 2.58, 3.00]
    },
    "Annual Results": {
      "Sales": [171, 205, 218, 223, 231, 327, 370, 410, 657, 680, 646, 473, 508],
      "Expenses": [158, 186, 189, 193, 200, 288, 327, 362, 521, 561, 534, 397, 423],
      "Operating Profit": [13, 19, 29, 30, 31, 39, 43, 48, 136, 119, 112, 76, 85],
      "Net Profit": [-1, 2, 8, 8, 8, 15, 16, 25, 83, 71, 43, -84, -16],
      "EPS in Rs": [-1.18, 2.19, 8.34, 3.04, 2.83, 5.50, 5.91, 9.14, 30.11, 25.87, 15.59, -30.36, -6.06]
    },
    "Balance Sheet Highlights": {
      "Equity Capital": [2, 2, 2, 7, 7, 7, 7, 14, 14, 14, 14, 14, 16],
      "Reserves": [26, 28, 78, 82, 92, 107, 122, 164, 245, 315, 354, 265, 430],
      "Borrowings": [72, 72, 70, 81, 75, 87, 81, 91, 181, 257, 415, 333, 206],
      "Total Assets": [131, 145, 189, 209, 219, 268, 267, 343, 526, 721, 898, 765, 804]
    },
    "Cash Flow Summaries": {
      "Cash from Operating Activity": [14, 17, 28, 25, 22, 17, 25, 21, 44, 1, -22, 92],
      "Cash from Investing Activity": [-8, -9, -17, -31, -8, -12, -13, -28, -109, -75, -93, -11],
      "Cash from Financing Activity": [-7, -8, -11, 5, -13, 2, -13, 3, 75, 62, 131, -97],
      "Net Cash Flow": [-0, 1, -0, -0, 0, 7, -0, -4, 10, -12, 16, -16]
    }
  },
  "Ratios": {
    "Growth Ratios": {
      "Compounded Sales Growth (10 Years)": "9%",
      "Compounded Sales Growth (5 Years)": "5%",
      "Compounded Sales Growth (3 Years)": "-10%",
      "Compounded Sales Growth (TTM)": "-2%",
      "Compounded Profit Growth (10 Years)": "Information not available",
      "Compounded Profit Growth (5 Years)": "Information not available",
      "Compounded Profit Growth (3 Years)": "Information not available",
      "Compounded Profit Growth (TTM)": "-15%"
    },
    "Liquidity Ratios": {
      "Current Ratio": "Information not available",
      "Quick Ratio": "Information not available"
    },
    "Profitability Ratios": {
      "Gross Profit Margin": "Information not available",
      "Operating Profit Margin": "Information available in quarterly and annual results",
      "Net Profit Margin": "Information available in quarterly and annual results",
      "Return on Equity (10 Years)": "13%",
      "Return on Equity (5 Years)": "14%",
      "Return on Equity (3 Years)": "8%",
      "Return on Equity (Last Year)": "-12%",
      "ROCE (10 Years)": "5%",
      "ROCE (5 Years)": "10%",
      "ROCE (3 Years)": "16%",
      "ROCE (Last Year)": "8%"
    },
    "Valuation Ratios": {
      "Price to Earnings Ratio": "49.3",
      "Price to Book Ratio": "Information not explicitly stated but implied by the cons section"
    },
    "Other Ratios": {
      "Debtor Days": [95, 98, 86, 70, 83, 90, 77, 88, 55, 99, 110, 139],
      "Inventory Days": [43, 51, 50, 56, 45, 57, 45, 54, 94, 143, 199, 206],
      "Days Payable": [51, 68, 63, 46, 51, 74, 45, 80, 67, 94, 81, 128],
      "Cash Conversion Cycle": [87, 81, 73, 80, 78, 73, 77, 62, 82, 148, 228, 217],
      "Working Capital Days": [71, 62, 52, 52, 58, 61, 66, 76, 90, 142, 208, 226]
    }
  },
  "Peer Comparison": {
    "Peers": [
      {"Name": "Sun Pharma.Inds.", "CMP": 1808.85, "P/E": 38.73, "Mar Cap": 434003.71, "Div Yld": 0.75, "NP Qtr": 3037.33, "Qtr Profit Var": 27.86, "Sales Qtr": 13291.39, "Qtr Sales Var": 9.01, "ROCE": 17.32},
      {"Name": "Cipla", "CMP": 1472.05, "P/E": 25.81, "Mar Cap": 118884.82, "Div Yld": 0.88, "NP Qtr": 1305.01, "Qtr Profit Var": 15.18, "Sales Qtr": 7051.02, "Qtr Sales Var": 5.58, "ROCE": 22.80},
      {"Name": "Mankind Pharma", "CMP": 2805.20, "P/E": 56.07, "Mar Cap": 112393.74, "Div Yld": 0.00, "NP Qtr": 634.43, "Qtr Profit Var": 34.84, "Sales Qtr": 2529.74, "Qtr Sales Var": 11.91, "ROCE": 24.57},
      {"Name": "Dr Reddy's Labs", "CMP": 1343.65, "P/E": 21.00, "Mar Cap": 112115.62, "Div Yld": 0.60, "NP Qtr": 1341.90, "Qtr Profit Var": -15.28, "Sales Qtr": 8038.20, "Qtr Sales Var": 16.45, "ROCE": 26.53},
      {"Name": "Lupin", "CMP": 2150.70, "P/E": 37.36, "Mar Cap": 98114.41, "Div Yld": 0.37, "NP Qtr": 859.48, "Qtr Profit Var": 74.12, "Sales Qtr": 5672.73, "Qtr Sales Var": 12.59, "ROCE": 15.72},
      {"Name": "Zydus Lifesci.", "CMP": 973.50, "P/E": 22.90, "Mar Cap": 97956.88, "Div Yld": 0.31, "NP Qtr": 920.20, "Qtr Profit Var": 13.62, "Sales Qtr": 5237.00, "Qtr Sales Var": 19.87, "ROCE": 22.34},
      {"Name": "Aurobindo Pharma", "CMP": 1241.70, "P/E": 19.96, "Mar Cap": 72756.00, "Div Yld": 0.36, "NP Qtr": 816.95, "Qtr Profit Var": 8.65, "Sales Qtr": 7796.07, "Qtr Sales Var": 7.99, "ROCE": 14.10}
    ],
    "Median": {
      "CMP": 512.7,
      "P/E": 33.34,
      "Mar Cap": 2869.55,
      "Div Yld": 0.05,
      "NP Qtr": 17.27,
      "Qtr Profit Var": 19.36,
      "Sales Qtr": 188.19,
      "Qtr Sales Var": 9.43,
      "ROCE": 14.1
    }
  },
  "Other Insights": {
    "Pros": [
      "Company has reduced debt."
    ],
    "Cons": [
      "Stock is trading at 3.78 times its book value",
      "Promoter holding has decreased over last quarter: -8.54%",
      "The company has delivered a poor sales growth of 5.04% over past five years.",
      "Company has a low return on equity of 7.77% over last 3 years."
    ],
    "Disclaimer": "The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.",
    "Shareholding Pattern Notes": "* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards. Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes."
  },
  "Announcements": [
    {"Title": "Clarification On Price Movement", "Date": "1d", "Description": "Clarification on recent price movement and compliance. Clarification sought from Bajaj Healthcare Ltd"},
    {"Title": "Clarification sought from Bajaj Healthcare Ltd", "Date": "1d", "Description": "Exchange has sought clarification from Bajaj Healthcare Ltd on December 19, 2024 with reference to significant movement in price, in order to ensure that investors …"},
    {"Title": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation", "Date": "2d", "Description": "One-on-one meeting with LIC Mutual Fund scheduled."},
    {"Title": "Company Entering Into A CDMO Contract With UK/ EU Based Companies", "Date": "9 Dec", "Description": "Bajaj Healthcare enters CDMO contract for 15 new APIs."},
    {"Title": "Approval From Therapeutic Goods Administration (TGA), Australia", "Date": "6 Dec", "Description": "Bajaj Healthcare's API site approved by TGA, Australia."}
  ]
}
